论文部分内容阅读
目的:探讨c-Met的表达规律,与乳腺癌术前新辅助化疗的敏感性和预后的关系。方法:采用免疫组织化学染色方法(SP法)检测147例乳腺癌组织中c-Met的表达,分析c-met的表达与各临床病理因素及术前新辅助化疗敏感性的关系;结合随访资料,分析c-Met表达对乳腺癌生存率的影响。结果:乳腺癌组织c-Met的阳性表达与组织学分级、淋巴结转移、肿瘤分期显著相关(P<0.05),与化疗敏感性及预后相关。结论:c-Met表达与乳腺癌腋窝淋巴结转移及化疗敏感性有关,可作为乳腺癌预后判断的辅助指标。
Objective: To investigate the relationship between the expression of c-Met and the sensitivity and prognosis of neoadjuvant chemotherapy before breast cancer. Methods: The expression of c-Met in 147 cases of breast cancer was detected by immunohistochemical staining (SP method), the relationship between c-met expression and clinicopathological factors and the sensitivity of preoperative neoadjuvant chemotherapy was analyzed. According to the follow-up data , Analysis of c-Met expression of breast cancer survival rate. Results: The positive expression of c-Met in breast cancer was significantly associated with histological grade, lymph node metastasis and tumor staging (P <0.05), which was correlated with the sensitivity and prognosis of chemotherapy. Conclusion: The expression of c-Met is correlated with the axillary lymph node metastasis and chemosensitivity in breast cancer and may be used as an adjunct to predict the prognosis of breast cancer.